A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)

November 18, 2026 updated by: Insmed Incorporated

INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators

The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.

Study Overview

Status

Recruiting

Study Type

Observational

Enrollment (Estimated)

69

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nottingham, United Kingdom, NG7 2UH
        • Recruiting
        • GBR001
    • California
      • Los Angeles, California, United States, 90095
        • Not yet recruiting
        • USA004
    • Maryland
      • Baltimore, Maryland, United States, 21287-0005
        • Recruiting
        • USA002
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Recruiting
        • USA001
    • Texas
      • Houston, Texas, United States, 77030-3008
        • Recruiting
        • USA003

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 10 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.

Description

Inclusion Criteria for the AT Cohort:

  • Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
  • If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.

Inclusion Criteria for the Healthy Comparator Cohort:

  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.

Exclusion Criteria for the AT Cohort:

  • Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.

Exclusion Criteria for the Healthy Comparator Cohort:

  • Diagnosis of any form of AT.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
AT Cohort

Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.

Healthy Comparator Cohort

Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Time Frame: Baseline up to Month 24
Baseline up to Month 24
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Time Frame: Baseline up to Month 24
Baseline up to Month 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Height
Time Frame: Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Weight
Time Frame: Baseline up to Month 24
Baseline up to Month 24
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Time Frame: Up to Month 24
Up to Month 24
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Time Frame: Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Motor Activity Assessed by Wearable Device
Time Frame: Baseline up to Month 24

A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity.

Baseline up to Month 24
Change From Baseline in Arm Function Assessed by Hevelius Test
Time Frame: Baseline up to Month 24
Baseline up to Month 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Study Director, Insmed Incorporated

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2026

Primary Completion (Estimated)

May 30, 2029

Study Completion (Estimated)

May 30, 2029

Study Registration Dates

First Submitted

October 30, 2026

First Submitted That Met QC Criteria

November 18, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 18, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe